| Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a diversified line of healthcare products. It has four segments. The Pharmaceutical Products segment's products include adult and pediatric pharmaceuticals. The Diagnostic Products segment's products include diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physicians' offices, alternate care testing sites, plasma protein therapeutic companies and consumers. The Nutritional Products segment's products include a line of pediatric and adult nutritional. The Vascular Products segment's products include a line of coronary, endovascular and vessel closure devices. In February 2008, the United States Food and Drug Administration (FDA) approved the Company's SIMCOR (Niaspan/simvastatin), a medicine for cholesterol management. In January 2008, Abbott's HUMIRA (adalimumab) received approval from FDA, for moderate to severe chronic plaque psoriasis. |
